美康生物
(300439)
| 流通市值：29.79亿 | | | 总市值：39.20亿 |
| 流通股本：2.92亿 | | | 总股本：3.84亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,406,709,821.37 | 949,125,024.71 | 481,512,053.72 | 1,885,869,216.24 |
| 营业收入 | 1,406,709,821.37 | 949,125,024.71 | 481,512,053.72 | 1,885,869,216.24 |
| 二、营业总成本 | 1,191,514,043.79 | 783,304,290.35 | 412,341,013.66 | 1,661,436,545.22 |
| 营业成本 | 762,448,197.92 | 507,936,055.55 | 278,005,340.56 | 1,044,688,488.54 |
| 税金及附加 | 13,184,164.56 | 7,961,419.08 | 3,984,164.36 | 19,152,132.4 |
| 销售费用 | 189,442,033.35 | 118,840,193.78 | 54,713,228.15 | 262,518,784.98 |
| 管理费用 | 118,152,270.43 | 77,100,369.36 | 39,870,866.41 | 186,994,968.06 |
| 研发费用 | 114,751,323.89 | 76,369,719.17 | 38,296,282.28 | 149,801,308.32 |
| 财务费用 | -6,463,946.36 | -4,903,466.59 | -2,528,868.1 | -1,719,137.08 |
| 其中:利息费用 | 1,514,399 | 1,277,023.67 | 338,362.53 | 10,663,476.73 |
| 其中:利息收入 | 7,851,136.02 | 6,333,311.8 | 2,992,695.87 | 13,270,425.14 |
| 加:公允价值变动收益 | 380,288.89 | 213,263.89 | 201,200 | - |
| 加:投资收益 | 14,474,621.09 | 8,533,476.56 | 1,680,076.74 | 14,927,419.15 |
| 资产处置收益 | 8,580.98 | 8,580.98 | 16,897.5 | -782,381.79 |
| 资产减值损失(新) | -1,601,744.14 | -1,465,535.74 | -747,170.34 | -21,271,425.23 |
| 信用减值损失(新) | 4,900,206.55 | 1,950,491.29 | 8,116,072.78 | 31,550,963.53 |
| 其他收益 | 16,854,995.32 | 12,104,348.05 | 6,656,517.7 | 30,259,482.91 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 250,212,726.27 | 187,165,359.39 | 85,094,634.44 | 279,116,729.59 |
| 加:营业外收入 | 9,159,902.01 | 9,005,869.02 | 2,467,211.92 | 19,234,119.15 |
| 减:营业外支出 | 4,392,548.76 | 1,461,982.94 | 1,325,030.62 | 2,671,715.99 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 254,980,079.52 | 194,709,245.47 | 86,236,815.74 | 295,679,132.75 |
| 减:所得税费用 | 31,650,540.8 | 16,383,586.45 | 8,184,704.67 | 36,179,157.28 |
| 六、净利润 | 223,329,538.72 | 178,325,659.02 | 78,052,111.07 | 259,499,975.47 |
| 持续经营净利润 | 223,329,538.72 | 178,325,659.02 | 78,052,111.07 | 259,499,975.47 |
| 归属于母公司股东的净利润 | 224,363,611.78 | 178,463,238.99 | 79,096,771.2 | 256,551,420.89 |
| 少数股东损益 | -1,034,073.06 | -137,579.97 | -1,044,660.13 | 2,948,554.58 |
| (一)基本每股收益 | 0.58 | 0.46 | 0.21 | 0.67 |
| (二)稀释每股收益 | 0.58 | 0.46 | 0.21 | 0.67 |
| 八、其他综合收益 | -4,248,904.58 | -5,244,221.58 | 20,524.12 | -4,744,187.07 |
| 归属于母公司股东的其他综合收益 | -3,242,176.08 | -3,641,276.68 | 22,343.47 | -4,006,004.46 |
| 九、综合收益总额 | 219,080,634.14 | 173,081,437.44 | 78,072,635.19 | 254,755,788.4 |
| 归属于母公司股东的综合收益总额 | 221,121,435.7 | 174,821,962.31 | 79,119,114.67 | 252,545,416.43 |
| 归属于少数股东的综合收益总额 | -2,040,801.56 | -1,740,524.87 | -1,046,479.48 | 2,210,371.97 |
| 公告日期 | 2024-10-26 | 2024-08-29 | 2024-04-24 | 2024-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |